 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the European Patent Office has issued an Intention to Grant notice for the first European patent covering Anixas novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute and is being developed at the Moffitt Cancer Center. 